MedTrace Logo

The Predictive Value of CT-PET in Esophageal Cancer

NCT02385604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2016-03-10

No results posted yet for this study

Summary

A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative approaches, in addition to identifying cohorts who are resistant to the neoadjuvant therapy. The current gold standard for determining response to CRT is pathological evaluation following surgical resection, in particular the Mandard Tumour Regression Grade (TRG) or some modification thereof. At this time, however, there is no preclinical early response or post-treatment biomarker, nor endoscopic or radiologic assessment that predicts pathologic response prior to surgical resection.The aim of this study is to determine the accuracy of CT-PET for prediction of histopathologic response and/or oncologic outcome for patients with esophageal cancer.

Conditions

  • Esophageal Neoplasms

Sponsors & Collaborators

  • St. James's Hospital, Ireland

    lead OTHER

Principal Investigators

  • John V Reynolds, MCh FRCS · Department of Surgery, St. James's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385604 on ClinicalTrials.gov